{
  "id": 1587,
  "text": "1154 (2014), OS overall survival, nr not reported, PFS progression-free survival Original studies presenting survival and response rates data according to NACT regimens administered in patients with LACC (continued) <html><body><table><tr><td>Authorreference</td><td>Year</td><td>N</td><td>Drugs</td><td>Response</td><td colspan=\"2\">Survival (%)</td></tr><tr><td></td><td></td><td></td><td></td><td>rate (%)</td><td>PFS</td><td>OS</td></tr><tr><td>Taneja et al.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: 1154 (2014), OS overall survival, nr not reported, PFS progression-free survival Original studies presenting survival and response rates data according to NACT regimens administered in patients with LACC (continued) <html><body><table><tr><td>Authorreference</td><td>Year</td><td>N</td><td>Drugs</td><td>Response</td><td colspan=\"2\">Survival (%)</td></tr><tr><td></td><td></td><td></td><td></td><td>r\n\n<question>: ",
  "ChatGPT_response_0": "在患有局部晚期宫颈癌的患者中，根据不同的新辅助化疗方案给药，有研究显示某些方案在生存率和疾病进展无病生存期表现上表现更好。例如，一些研究指出使用某些药物方案后，患者的生存率得到显著提高，且疾病进展无病生存期明显延长。因此，在选择新辅助化疗方案时，应该考虑患者的具体情况和病理特征，以确保选择最适合的治疗方案，从而提高患者的生存率和延长无病进展生存期。",
  "query": "在患有局部晚期宫颈癌的患者中，根据不同的新辅助化疗方案给药，哪种方案的生存率和疾病进展无病生存期表现更好？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 在患有局部晚期宫颈癌的患者中，根据不同的新辅助化疗方案给药，哪种方案的生存率和疾病进展无病生存期表现更好？\n\n<reference text>: 1154 (2014), OS overall survival, nr not reported, PFS progression-free survival Original studies presenting survival and response rates data according to NACT regimens administered in patients with LACC (continued) <html><body><table><tr><td>Authorreference</td><td>Year</td><td>N</td><td>Drugs</td><td>Response</td><td colspan=\"2\">Survival (%)</td></tr><tr><td></td><td></td><td></td><td></td><td>rate (%)</td><td>PFS</td><td>OS</td></tr><tr><td>Taneja et al.\n\n<reply>: ",
  "response": "在患有局部晚期宫颈癌的患者中，根据不同的新辅助化疗方案给药，有研究显示某些方案在生存率和疾病进展无病生存期表现上表现更好。例如，一些研究指出使用某些药物方案后，患者的生存率得到显著提高，且疾病进展无病生存期明显延长。因此，在选择新辅助化疗方案时，应该考虑患者的具体情况和病理特征，以确保选择最适合的治疗方案，从而提高患者的生存率和延长无病进展生存期。"
}